LBRX (LB Pharmaceuticals) Buildings And Improvements: $3.41 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $47.87
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Buildings And Improvements?

LB Pharmaceuticals LBRX +7.87% 12 Buildings And Improvements is $3.41 Mil as of Jun. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

LB Pharmaceuticals's quarterly buildings and improvements increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($2.10 Mil) and increased from Mar. 2026 ($2.10 Mil) to Jun. 2026 ($3.41 Mil).

LB Pharmaceuticals Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Buildings And Improvements Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
0.00 0.00 0.00 0.00

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.20 0.00 2.10 3.41
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $3.41 Mil mean?
LB Pharmaceuticals (LBRX) has a Buildings And Improvements of $3.41 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Buildings And Improvements too high?
LB Pharmaceuticals' current Buildings And Improvements is $3.41 Mil. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Buildings And Improvements compare to MRVI and LXRX?
LB Pharmaceuticals' Buildings And Improvements of $3.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Buildings And Improvements is $3.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Buildings And Improvements of $3.41 Mil. The current Buildings And Improvements is $3.41 Mil. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Buildings And Improvements is $3.41 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.87
Price